zurück

Efgartigimod alfa (Myasthenia Gravis for AChR antibody positive patients)

 

Subject:

  • Active Sustance: Efgartigimod alfa
  • Name: Vyvgart®
  • Therapeutic area: Myasthenia Gravis
  • Pharmaceutical company: Argenx Germany GmbH

 

Time table:

  • Start: 01.09.2022
  • Publication of assessment: 01.12.2022
  • End of public hearing: 22.12.2022
  • Final decision by G-BA: middle of February 2023

 

Comparative therapy:

  • No comparative therapy due to orphan drug designation